Effects of Eradication of HCV on Cardiovascular Risk and Preclinical Atherosclerosis in HIV/HCV-Coinfected Patients

• Published in: Journal of acquired immune deficiency syndromes (1999) Vol. 83; no. 3; p. 292
• Main Authors: Carrero, Ana, Berenguer, Juan, Hontañón, Víctor, Navarro, Jordi, Hernández-Quero, José, Galindo, María J, Quereda, Carmen, Santos, Ignacio, Téllez, María J, Ortega, Enrique, Sanz, José, Medrano, Luz M, Pérez-Latorre, Leire, Bellón, José M, Resino, Salvador, Bermejo, Javier, González-García, Juan
• Format: Journal Article
• Language: English
• Published: United States 01.03.2020
• Subjects: Antiviral Agents - therapeutic use; Atherosclerosis - complications; Atherosclerosis - prevention & control; Biomarkers; Cardiovascular Diseases - complications; Cardiovascular Diseases - prevention & control; Coinfection; Female; Hepatitis C - complications; Hepatitis C - drug therapy; HIV Infections - complications; Humans; Inflammation - blood; Inflammation - metabolism; Male; Middle Aged
• ISSN: 1944-7884
• DOI: 10.1097/QAI.0000000000002260

To assess the effects of eradication of hepatitis C virus (HCV) on cardiovascular risk (CVR) and preclinical atherosclerosis in HIV/HCV-coinfected patients. Prospective cohort study. We assessed serum lipids, 10-year Framingham CVR scores, pulse wave velocity, carotid intima-media thickness, and biomarkers of inflammation and endothelial dysfunction (BMKs) at baseline and 96 weeks (wk) after initiation of anti-HCV therapy (Rx) in HIV/HCV-coinfected patients. A total of 237 patients were included. Anti-HCV therapy comprised pegylated interferon and ribavirin plus 1 direct-acting antiviral in 55.2%, pegylated interferon and ribavirin in 33.8%, and all-oral direct-acting antiviral in 11.0%. A total of 147 (62.0%) patients achieved sustained viral response (SVR). Median increases in low-density lipoprotein cholesterol in patients with and without SVR were 14 mg/dL and 0 mg/dL (P = 0.024), respectively. Increases in CVR categories were found in 26.9% of patients with SVR (P = 0.005 vs. baseline) and 8.1% of patients without SVR (P = 0.433). This resulted in a significant interaction between SVR and CVR over time (P < 0.001). No significant effect of SVR was observed for pulse wave velocity (P = 0.446), carotid intima-media thickness (P = 0.320), and BMKs of inflammation and endothelial dysfunction. In coinfected patients, eradication of HCV had no effect on markers of preclinical atherosclerosis and BMKs of inflammation and endothelial dysfunction but was associated with a clinically relevant rise in serum low-density lipoprotein cholesterol. Evaluation of CVR should be an integral part of care after the cure of chronic hepatitis C in patients with HIV.